Posted by Michael Wonder on 25 Sep 2017
Camurus announces that FDA grants priority review of NDA for weekly and monthly CAM2038 buprenorphine depots for treatment of opioid use disorder
18 September 2017 - Camurus announces that the U.S. FDA has accepted the new drug application for weekly and monthly CAM2038 buprenorphine depots for the treatment of adults with opioid use disorder and granted a priority review.
The NDA for CAM2038 was submitted on 19 July 2017 by Camurus’ U.S. partner Braeburn Pharmaceuticals and comprises data from seven clinical trials, including two Phase 3 trials.
